Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

I was expecting to see some details of Casgevy's revenue performance since it was approved to treat Sickle Cell Disease (“SCD”) in December last year, and to treat transfusion dependent beta ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next ...

"Casgevy offers an effective cure for transfusion-dependent beta thalassaemia for people without a stem cell donor," she added, whilst pointing out there is also a desperate need for new options ...

Esther Nkemakolam runs her fingers through kinetic sand and sings a “Moana” song as UPMC Children’s Hospital nurse Taylor ...

Casgevy, was approved in late 2023/early 2024 for two blood disorders — sickle cell disease and transfusion-dependent beta thalassemia — in the United States, Europe and several other countries.

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

Developed in collaboration with Vertex Pharmaceuticals, Casgevy was approved in late 2023/early 2024 for two indications — sickle cell disease (SCD) and transfusion-dependent beta-thalassemia ...

The company, in collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), has reported progress in the launch of Casgevy for sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT).